

Sheet 1 of 4

FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-15110	Serial No 10/517,010
	Applicants Michael Joseph Coghlan, et al.	
	Filing Date December 3, 2004	Group 1654

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/S.L./	AA	3,351,588	November 7, 1967	Davis, et al.	
	AB	3,519,621	July 7, 1970	Humber, et al.	
	AC	4,999,363	March 12, 1991	Oshima, et al.	
	AD	6,362,188	March 26, 2002	Guzi, et al.	
	AE	4,282,233	August 4, 1981	Vilani	
	AF	5,024,912	June 18, 1991	Neishi, et al.	
	AG	5,093,210	March 3, 1992	Ohta, et al.	
	AH	5,378,701	January 3, 1995	Ohshima, et al.	
	AI	3,205,264	September 7, 1965	Tristram, et al.	
	AJ	5,726,325	March 10, 1998	Yoshida, et al.	
	AK	4,963,450	October 16, 1990	Miyazaki, et al.	
	AL	6,289,190	September 11, 2001	Amamiya, et al.	
	AM	3,859,356	January 7, 1975	Houlihan, et al.	
↓	AN	5,151,545	September 29, 1992	McCarthy, et al.	

FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ - Kind Code ⁵ (if known)				
/S.L./	BA	WO 00/06137	February 10, 2000	Abbott Laboratories		

Examiner Signature	/Sun Jae Loewe/	Date Considered	10/05/2007
-----------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Atty. Docket No. X-15110	Serial No 10/517,010
		Applicants Michael Joseph Coghlan, et al.	
		Filing Date December 3, 2004	Group 1654

/S.L./	BB	GB 1 501 321	February 15, 1978	Sumitomo Chemical		
	BC	GB 1 001 822	August 18, 1965	Sandoz		
	BD	GB 1 242 096	August 11, 1971	Labaz		
	BE	GB 1 043 158	September 21, 1966	Sandoz		
	BF	WO 99/33786	July 8, 1999	Ortho-McNeil		
	BG	WO 00/59884	October 12, 2000	Dana-Farber Cancer Inst.		
	BH	EP 0 549 352	March 1, 2000	Kyowa Hakko Kogyo Co.		
	BI	WO 97/11071	March 27, 1997	Novo Nordisk		
	BJ	JP 01161245	June 23, 1989	Canon Inc.		Yes
	BK	JP 04046352	February 17, 1992	Minolta Camera Co., Ltd.		Yes
	BL	JP 05002278	January 8, 1993	Konica Corp.		Yes
	BM	JP 09101200	April 15, 1997	Canon Inc.		Yes
	BN	JP 02113258	April 25, 1990	Canon Inc.		Yes
	BO	JP 2001089680	April 3, 2001	Fuji Photo Film Co., Ltd.		Yes
	BP	JP 05281765	October 29, 1993	Kao Corp.		Yes
	BQ	JP 02032358	February 2, 1990			
	BR	WO 02/096893	December 5, 2002	Glaxo Group Limited		
	BS	WO 02/009759	February 7, 2002	Pharmacia Corporation		
	BT	WO 01/95892	December 20, 2001	Pharmacia Corporation		
↓	BU	WO 02/17895	March 7, 2002	Pharmacia Corporation		

Examiner Signature	/Sun Jae Loewe/	Date Considered	10/05/2007
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FORM PTO 1449 (modified)	Atty. Docket No. X-15110	Serial No 10/517,010
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicants Michael Joseph Coghlan, et al.	
	Filing Date December 3, 2004	Group 1654


NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T ⁶
/S.L./	CA	Werner, et al., "Imidazoline derivatives with antiarrhythmic activity," Journal of Medicinal Chemistry, Vol. 10, No. 4, pgs. 575-582; XP002283810 (1967)	
	CB	Gadient, et al., "Uber neuartige tricyclische Thiazepin- und Thiepin-Derivate," Helvetica Chimica ACTA, Vol. 45, No. 6, pgs. 1860-1870; XP002283811 (1962)	
	CC	Villani, et al., "Derivatives of 12,11-dihydro-5H-dibenzo'a,d!cycloheptene and related compounds. II" Journal of Medicinal Chemistry, Vol. 7, No. 4, pgs. 457-460; XP002283812 (1964)	
	CD	Bille-Same, et al., "Fulvenes et ethylenes thermochromes. LXXII. (1) Observations dans la serie du dibenzo'a,d!cyclohepta'1,4!diene," Bulletin De La Societe Chimique De France, No. 11, pgs. 4212-4214; XP002283813 (1972)	
	CE	Cordi, et al., "Synthesis and structure-activity of 4(5)-(2-2-diphenylethyl)imidazoles as new alpha2-adrenoreceptor agonists," European Journal of Medicinal Chemistry, Vol. 25, No. 7, pgs. 557-568; XP002283814 (1990)	
	CF	Cheng, et al., "Synthesis and structure-activity relationships of 9-substituted acridines as endothelin-A receptor antagonists," Biorganic & Medicinal Chemistry Letters, Vol. 6, No. 24, pgs. 2999-3002; XP002283815 (1996)	
	CG	Bastian, et al., "4H-Benzo '4,5!cyclohepta'1,2-b!thiophene," Helvetica Chimica ACTA, Vol. 49, pgs. 214-234; XP002263672 (1966)	
	CH	Daich, et al., "On the synthesis and reactivity of 4,10-dihydrobenzo'b!thieno-'2,3-e!thiepin-10-acetic acid and 5,10-dihydrobenzo'e!thieno'2,3-b!thiepin-10-acetic acid," Journal of Heterocyclic Chemistry, Vol. 29, No. 7, pgs. 1789-1795; XP002283816 (1992)	
	CI	Polman, et al., "Photoaddition of aromatic ketones to some arylacetylenes; formation of alpha,beta-unsaturated ketones and aldehyde," Recueil Des Travaux Chimiques Des Pays-Bas, Vol. 92, pgs 845-854; XP008031504 (1973)	
	CJ	Wittig, et al., "Uber Ringerweiterung und Ringverengerung auf der Basis von Ylidisomerisationen," Justus Liebigs Annalen Der Chemie, Vol. 594, pgs. 89-118; XP008031512 (1955)	
	CK	Davis, et al., "New psychotropic agents. VIII. Analogues of amitriptyline containing the normeperidine group," Journal of Medicinal Chemistry, Vol. 10, No. 4, pgs. 627-635; XP002284192 (1967)	
↓	CL	R. G. Micetich, "Lithiation of five-membered heteroaromatic compounds. The methyl substituted 1,2-azoles, oxadiazoles, and thiadiazoles," Canadian Journal of Chemistry, Vol. 48, No. 13, pgs. 2006-2015 (1970)	

Examiner Signature	/Sun Jae Loewe/	Date Considered	10/05/2007
-----------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Atty. Docket No. X-15110	Serial No 10/517,010
		Applicants Michael Joseph Coghlan, et al.	
		Filing Date December 3, 2004	Group 1654

/S.L./	CM	Bergmann, et al., "Fulvenes and Thermochemical Ethylenes. Part 57. The Wittig-Horner Reaction with Fulvene Ketones and Related Ketones," Synthesis, Vol. 2, No. 4, pgs. 183-189 (1970)	
↓	CN	Fox, et al., "Synthetic Antigonadotropines. II," J. Med. Chem, Vol. 7, No. 6, pgs. 790-792 (1964)	
↓	CO	Boris, et al., "Antigonadotropic Activity of Some Substituted Triphenylethylene Derivatives," Arch. Intern. Pharmacodyn, Vol. 151, No. 3-4, pgs. 475-489 (1964)	
↓	CP	Bergmann, et al., "Fulvenes and Thermochemical Ethylenes. XXXIII. Polycyclic Derivatives of Heptafulvene," J. Org. Chem, Vol. 28, No. 12, pgs. 3341-3343 (1963)	
↓	CQ	Rabinovitz, J. Chem. Soc., Perkin Transactions 2: Physical Organic Chemistry, Vol. 12, pgs 1836-1838 (1972)	

Examiner Signature	/Sun Jae Loewe/	Date Considered	10/05/2007
-----------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.